Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans - PubMed (original) (raw)
. 2007 Sep;293(3):E849-56.
doi: 10.1152/ajpendo.00289.2007. Epub 2007 Jul 3.
Affiliations
- PMID: 17609256
- DOI: 10.1152/ajpendo.00289.2007
Free article
Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans
Juris J Meier et al. Am J Physiol Endocrinol Metab. 2007 Sep.
Free article
Abstract
Changes in hepatic insulin clearance can occur after oral glucose or meal ingestion. This has been attributed to the secretion and action of gastric inhibitory polypeptide (GIP) and glucagon-like peptide (GLP)-1. Given the recent availability of drugs based on incretin hormones, such clearance effects may be important for the future treatment of type 2 diabetes. Therefore, we determined insulin clearance in response to endogenously secreted and exogenously administered GIP and GLP-1. Insulin clearance was estimated from the molar C-peptide-to-insulin ratio calculated at basal conditions and from the respective areas under the curve after glucose, GIP, or GLP-1 administration. Oral glucose administration led to an approximately 60% reduction in the C-peptide-to-insulin ratio (P < 0.0001), whereas intravenous glucose administration had no effect (P = 0.09). The endogenous secretion of GIP or GLP-1 was unrelated to the changes in insulin clearance. The C-peptide-to-insulin ratio was unchanged after the intravenous administration of GIP or GLP-1 in the fasting state (P = 0.27 and P = 0.35, respectively). Likewise, infusing GLP-1 during a meal course did not alter insulin clearance (P = 0.87). An inverse nonlinear relationship was found between the C-peptide-to-insulin ratio and the integrated insulin levels after oral and during intravenous glucose administration. Insulin clearance is reduced by oral but not by intravenous glucose administration. Neither GIP nor GLP-1 has significant effects on insulin extraction. An inverse relationship between insulin concentrations and insulin clearance suggests that the secretion of insulin itself determines the rate of hepatic insulin clearance.
Similar articles
- Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
Vollmer K, Holst JJ, Baller B, Ellrichmann M, Nauck MA, Schmidt WE, Meier JJ. Vollmer K, et al. Diabetes. 2008 Mar;57(3):678-87. doi: 10.2337/db07-1124. Epub 2007 Dec 5. Diabetes. 2008. PMID: 18057091 - Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on beta-cell secretion and insulin clearance in mice.
Pacini G, Thomaseth K, Ahrén B. Pacini G, et al. Metabolism. 2010 Jul;59(7):988-92. doi: 10.1016/j.metabol.2009.10.021. Epub 2010 Feb 12. Metabolism. 2010. PMID: 20153002 - Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
Nauck MA, El-Ouaghlidi A, Gabrys B, Hücking K, Holst JJ, Deacon CF, Gallwitz B, Schmidt WE, Meier JJ. Nauck MA, et al. Regul Pept. 2004 Nov 15;122(3):209-17. doi: 10.1016/j.regpep.2004.06.020. Regul Pept. 2004. PMID: 15491793 - Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.
Dupre J. Dupre J. Regul Pept. 2005 Jun 15;128(2):149-57. doi: 10.1016/j.regpep.2004.06.003. Regul Pept. 2005. PMID: 15780434 Review. - The biology of incretin hormones.
Drucker DJ. Drucker DJ. Cell Metab. 2006 Mar;3(3):153-65. doi: 10.1016/j.cmet.2006.01.004. Cell Metab. 2006. PMID: 16517403 Review.
Cited by
- Insulin clearance and incretin hormones following oral and "isoglycemic" intravenous glucose in type 2 diabetes patients under different antidiabetic treatments.
Tura A, Göbl C, Vardarli I, Pacini G, Nauck M. Tura A, et al. Sci Rep. 2022 Feb 15;12(1):2510. doi: 10.1038/s41598-022-06402-5. Sci Rep. 2022. PMID: 35169165 Free PMC article. - Hepatic and Extrahepatic Insulin Clearance in Mice with Double Deletion of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Receptors.
Morettini M, Piersanti A, Burattini L, Pacini G, Göbl C, Ahrén B, Tura A. Morettini M, et al. Biomedicines. 2021 Aug 6;9(8):973. doi: 10.3390/biomedicines9080973. Biomedicines. 2021. PMID: 34440177 Free PMC article. - Dipeptidyl peptidase-4 inhibitor, anagliptin, alters hepatic insulin clearance in relation to the glycemic status in Japanese individuals with type 2 diabetes.
Abe T, Matsubayashi Y, Muragishi S, Yoshida A, Suganami H, Furusawa K, Fujihara K, Tanaka S, Kaku K, Sone H. Abe T, et al. J Diabetes Investig. 2021 Oct;12(10):1805-1815. doi: 10.1111/jdi.13543. Epub 2021 May 26. J Diabetes Investig. 2021. PMID: 33751849 Free PMC article. Clinical Trial. - The Measurement of Insulin Clearance.
Piccinini F, Bergman RN. Piccinini F, et al. Diabetes Care. 2020 Sep;43(9):2296-2302. doi: 10.2337/dc20-0750. Diabetes Care. 2020. PMID: 32910777 Free PMC article. Review. - Bromocriptine mesylate improves glucose tolerance and disposal in a high-fat-fed canine model.
Moore MC, Smith MS, Swift LL, Cincotta AH, Ezrokhi M, Cominos N, Zhang Y, Farmer B, Cherrington AD. Moore MC, et al. Am J Physiol Endocrinol Metab. 2020 Jul 1;319(1):E133-E145. doi: 10.1152/ajpendo.00479.2019. Epub 2020 May 27. Am J Physiol Endocrinol Metab. 2020. PMID: 32459527 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical